ScreenerHero

SLXNSilexion Therapeutics Ltd.

NAS · US · Healthcare · Biotechnology · silexion.com
0.3941USD-4.62%Mkt Cap: 2.19M $P/E: —

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of sol…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.19M $
Enterprise Value-247.94K $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-11.91M $
Revenue/Share—
Last Price0.3941 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.62
PEG—
EV/EBITDA0.02
EV/Revenue—
P/S—
P/B0.47
EPS (TTM)-19.89
EPS (Forward)-0.64
52W Range
0.37700% of range82.90
52W High82.90 USD
52W Low0.3770 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-457.63%
ROA-165.10%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.82M $
CapEx (TTM)9.00K $
FCF Margin—
FCF Yield-341.86%
Net Debt-424.00K $
Net Debt/EBITDA0.03
Balance Sheet
Debt/Equity0.78
Current Ratio1.00
Quick Ratio0.59
Book Value/Sh0.8570 USD
Cash/Share5.759 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateMay 29, 2026
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)60.00 USD
Upside (mean)+15124.6%
Target Range60.00 USD – 60.00 USD
# Analysts1
Ownership
Shares Out.5.56M
Float414.62K
Insiders7.61%
Institutions0.96%
Short Interest
Short Ratio0.3d
Short % Float2.41%
Short % Out.2.00%
Shares Short21.28K
Short (prev mo.)13.74K
Technical
SMA 502.162 (-81.8%)
SMA 20013.00 (-97.0%)
Beta-0.27
S&P 52W Chg18.16%
Avg Vol (30d)98.91K
Avg Vol (10d)1.02M
Technical Indicators
RSI (14)20.3
MACD-0.5154
MACD Signal-0.3934
MACD Hist.-0.1221
BB Upper3.349 USD
BB Middle2.031 USD
BB Lower0.7134 USD
BB Width129.76%
ATR (14)0.3481 USD
Vol Ratio (20d)1.60x